FindTrial
Sign In

Mechanism and clinical study of sevoflurane alleviating the occurrence and development of acute respiratory distress syndrome (ARDS)

Mechanism and clinical study of sevoflurane alleviating the occurrence and development of acute respiratory distress syndrome (ARDS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084667
Enrollment
Unknown
Registered
2024-05-22
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory distress syndrome

Interventions

Group sevoflurane (Group S):Group sevoflurane receiving inhaled sevoflurane.
Group midazolam (Group M):Group midazolam receiving intravenous injection of midazolam.

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 99 years old;2.Onset of moderate to severe ARDS within 24 hours (Berlin criteria);3.Patients with complete clinical records;4.Ethical compliance, voluntary participation of patients, and signing of informed consent forms.

Exclusion criteria

Exclusion criteria: 1.Patients under 18 years of age;2.Allergic to midazolam, sevoflurane, or cisatracurium;3.History of malignant hyperthermia.

Design outcomes

Primary

MeasureTime frame
Oxygenation index (PaO2/FiO2);—

Secondary

MeasureTime frame
Interleukin-6 (IL-6);tumor necrosis factor-a (TNF-a);—

Countries

China

Contacts

Public ContactFang Xiaobin

Fujian Provincial Hospital

39130727@qq.com+86 139 6033 7175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026